Approval based on results from CheckMate -901, the first Phase 3 trial in this patient population with an immunotherapy-chemotherapy combination to demonstrate survival benefit versus.
Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.
GFGF pays GH¢779,583 as fees for 325 university students ghanaiantimes.com.gh - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ghanaiantimes.com.gh Daily Mail and Mail on Sunday newspapers.